Application of anthracene nucleus antibiotic and its pharmaceutical salt for treating diabetic eye diseases
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for diabetic eye disease and antibiotics, applied in metabolic diseases, sensory diseases, drug combinations, etc., can solve the problems of no effect, obvious effect and no effect of retinopathy, and achieve the effect of avoiding various related eye diseases caused by the disease.
Active Publication Date: 2015-04-22
张雅珍
View PDF0 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0005] As mentioned above, although there are already many drugs and technologies for the treatment of diabetes-related eye diseases, the current drugs and treatment technologies are only effective for a single type of diabetes-related eye diseases, such as some drugs only for retinopathy Obvious, but not effective or mediocre for other eye diseases caused by diabetes, such as diabetic choroidopathy; and some drugs may be effective for diabetic optic atrophy, but have no effect for similar retinopathy
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0022] ① Take 300mg of poly(lactic-co-glycolic acid) (PLGA) and add it into 1ml of dichloromethane to prepare a solution;
[0023] ② Add 50 mg of arubicin to the solution prepared in ①, and stir with a high-speed homogenizer;
[0024] ③Use a syringe to slowly inject the solution in ② into the cottonseed oil containing 0.05% egg yolk oil, stir at 1000r / min for 20min, then reduce the speed to 200r / min and continue stirring for 4h;
[0025] ④Add 20ml petroleum ether to step ③, centrifuge at 8000r / min for 5min after 30min;
[0026] ⑤ Collect the microspheres, wash with petroleum ether and evaporate to dryness.
Embodiment 2
[0028] ① Take 200mg of poly(lactic-co-glycolic acid) (PLGA) and add it to 1ml of tetrahydrofuran solution to prepare a solution;
[0029] ② Add 50 mg of mitoxantrone to 0.2 ml of glycerin, mix well and add to the solution prepared in ①, stir with a homogenizer for 1 min to obtain colostrum;
[0030] ③Add it to 12ml of 2% polyvinyl alcohol (PVA) solution, stir at 1000r / min for 5min, then add 120ml of 0.5%PVA solution to obtain double emulsion;
[0031]④ Reduce the rotational speed to 200r / min and continue stirring for 4h, then centrifuge at 8000r / min for 5min;
[0032] ⑤ The microspheres were collected, washed with distilled water and freeze-dried.
Embodiment 3
[0034] ① Take 100mg of polyanhydride-polyethylene glycol copolymer (PSA-PEG) and add it to 1ml of dichloromethane solution to prepare a solution;
[0035] ② Add 50mg of doxorubicin to the solution prepared in ①, and mix it by ultrasonic;
[0036] ③ Add the solution prepared in ② into 15ml 1% PVA solution;
[0037] ④ Reduce the rotational speed to 200r / min and continue stirring for 4h, then centrifuge at 8000r / min for 5min;
[0038] ⑤ Collect microspheres, wash with distilled water and collect.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses an application of anthracene nucleus antibiotic and its pharmaceutical salt for treating diabetic eye diseases. The invention found that the anthracene nucleus antibiotic and its pharmaceutical salt have good effect on treatment of diabetic eye diseases, and especially the anthracene nucleus antibiotics can be prepared to prolonged action preparations such as a nano preparation, a microballoon preparation, liposome and hydrogel, the toxicity of anthracene nucleus antibiotic is reduced, and the anthracene nucleus antibiotic enables ophthalmic administration, administration dosage is simultaneously enlarged, the duration time of drug effect is long, the medicament curative effect is stronger than that of the common preparations of the anthracene nucleus antibiotic, when the ophthalmic administration is carried out, the anthracene nucleus antibiotic has good treatment effect for treating various eye diseases relative to diabetes, the medicine treatment is carried out when the diabetic eye diseases is found at initial stage, the deterioration of diseases can be avoided, the active treatment effect is provided, so that a surgery treatment method with large wound such as operation can be avoided.
Description
technical field [0001] The present invention relates to a medicine for treating diabetic eye disease, in particular to the new application of a series of traditional anti-tumor antibiotic anthracycline antibiotics and pharmaceutically acceptable salts thereof in the preparation of medicine for treating diabetic eye disease, in particular, the anthracycline antibiotic and Its pharmaceutically acceptable salt can be prepared into long-acting preparations such as nano preparations, microsphere preparations, liposomes and hydrogels. Background technique [0002] Diabetes is a series of metabolism of sugar, fat, protein, electrolyte, etc. caused by immune dysfunction, genetic factors, microbial infection and its toxins, free radical toxins, mental factors and other pathogenic factors acting on the body to cause hypofunction of pancreatic islets, etc. Disorder syndrome is clinically characterized by hyperglycemia, and typical cases may manifest as polyuria, polydipsia, polyphagia,...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more